Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by enriquesuaveon Jan 24, 2021 8:03pm
228 Views
Post# 32372232

Durable Response

Durable Response Let's hope we can continue to see durable response rates which extend well beyond one year mark.  It was good to see that all 3 patients from PH2 who had a CR at 3 months were still CR at 6 months mark after only one single treatment.  In general, all other competition showed a drop in CR from 3 to 6 months time point and a further drop at 9 and 12 months.   However a small 12 patient sample is still not yet enough to draw conclusions, but after the second treatment on the 7 remaining patients and the next round of patients it may definitely be possible.  If providing an optimized treatment leads to a CR in a majority of patients and most of these remain CR at 12-15 months, then we have ourselves a New Paradigm Shift in NMIBC treatments.  All IMO
<< Previous
Bullboard Posts
Next >>